S&P Futures
4,161.50 +31.00 (+0.75%) Dow Futures
34,207.00 +212.00 (+0.62%) Nasdaq Futures
12,689.00 +143.75 (+1.15%) Russell 2000 Futures
1,964.00 +14.10 (+0.72%) Crude Oil
78.53 +0.06 (+0.08%) Gold
1,893.90 +3.20 (+0.17%)
Ekso Bionics Holdings, Inc. (EKSO)
Chart Events
Performance Outlook
| Previous Close | 1.7800 |
| Open | 1.7900 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1000 |
| Day's Range | 1.7150 - 1.7900 |
| 52 Week Range | 1.0300 - 3.1500 |
| Volume | |
| Avg. Volume | 53,045 |
| Market Cap | 22.684M |
| Beta (5Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9260 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for EKSO
Related Research
- Ekso Bionics Holdings, Inc.Analyst Report: Parker-Hannifin Corp.Parker-Hannifin manufactures motion and control technologies and systems that are used to control fluids, gas, or air in hydraulic, pneumatic and vacuum applications. It sells its products to aerospace, commercial, and industrial customers, who use them to move materials and operate machines and vehicles. The company employs approximately 55,000 people. PH shares are a component of the S&P 500.RatingFair ValueEconomic Moat2 days agoArgus Research
- GlobeNewswire
Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego® Product Line From Parker Hannifin Corporation
Broadens Ekso Bionics’ product portfolio into home use Adds Vanderbilt University as a key commercial and research partner Acquisition consolidates leading lower extremity robotic companies Ekso President and COO Scott Davis promoted to Chief Executive Officer; Steven Sherman to remain Chairman, appointed Executive Chair SAN RAFAEL, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, t
- Simply Wall St.
Ekso Bionics Holdings Third Quarter 2022 Earnings: Misses Expectations
Ekso Bionics Holdings ( NASDAQ:EKSO ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.33m (up 9.2% from...
- Zacks
Ekso Bionics (EKSO) Reports Q3 Loss, Lags Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -37.50% and 7.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
